Paraneoplastic syndromes in lung cancer;Paraneoplastische syndrome beim lungenkarzinom

Pneumologie

Volumn 65, Issue 6, 2011, Pages 347-358

  Hauber, H P ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CLINICAL FEATURE; LUNG CANCER; PARANEOPLASTIC SYNDROME; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

CROSS-SECTIONAL STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PARANEOPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS;

EID: 79958827771     PISSN: 09348387     EISSN: 14388790     Source Type: Journal    
DOI: 10.1055/s-0030-1256118     Document Type: Review

References (165)

1. Bunn PA, Ridgway EC. Paraneoplastic syndromes. In: DeVita VT et al., eds. Cancer: Principles and Practice of Oncology. 4th edn. Philadelphia: Lippincott Co 1993: 2026-2071
2. Navani N, Spiro SG. Symptoms and signs of lung cancer. In: Spiro SG, Huber RM, Janes SM, eds. Thoracic Malignancies. Eur Respir Monograph 2009; 44: 71-87
3. Richardson GE, Johnson BE. Paraneoplastic syndromes in lung cancer. Curr Opin Oncol 1992; 4: 323-333
4. Heinemann S, Zabel P, Hauber HP. Paraneoplastic syndromes in lung cancer. Cancer Therapy 2008; 6: 687-698
5. Monsieur I, Meysman M, Noppen N et al. Non-small-cell lung cancer with multiple paraneoplastic syndromes. Eur Respir J 1995; 8: 1231-1234
6. Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132: 149S-160S
7. Hiraki A, Ueoka H, Takata I et al. Hypercalcemia-leukocytosis syndrome associated with lung cancer. Lung Cancer 2004; 43: 301-307 (Pubitemid 38224150)
8. Burtis WJ, Brady TG, Orloff JJ et al. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with hypercalcemia of cancer. N Engl J Med 1990; 322: 1106-1112 (Pubitemid 20149527)
9. Moseley JM, Kubota M, Diefenbach-Jagger H et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci 1987; 84: 5048-5052 (Pubitemid 17095861)
10. Abou-Samra AB, Juppner H, Force T et al. Expression cloning of a common receptor for parathyroid hormone and parathyroid hormonerelated peptide from rat osteoblast-like cells: a single receptor stimulates intracellular accumulation of both cAMP and inositol trisphosphates and increases intracellular free calcium. Proc Natl Acad Sci 1992; 89: 2732-2736
11. Horiuchi N, Caulfield MP, Fisher JE et al. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro. Science 1987; 238: 1566-1568 (Pubitemid 18032471)
12. Danks JA, Ebeling PR, Hayman J et al. Parathyroid hormone-related protein: immunohistochemical localization in cancers and in normal skin. J Bone Min Res 1989; 4: 273-278 (Pubitemid 19121804)
13. Asa SL, Henderson J, Goltzman D, Drucker DJ. Parathyroid hormone-like peptide in normal and neoplastic human endocrine tissues. J Clin Endocrinol Metab 1990; 71: 1112-1118
14. Clines GA, Guise TA. Hypercalcaemia ofmalignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis in bone. Endocr Rel Cancer 2005; 12: 549-583 (Pubitemid 41482993)
15. Juppner H, Abou-Samara AB, Freeman M et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991; 254: 1024-1026 (Pubitemid 21917436)
16. Mahon MJ, Donowitz M, Yun CC, Segre GV. Na(+)/H(+) exchanger regulatory factor 2 directs parathyroid hormone 1 receptor signalling. Nature 2002; 417: 858-861 (Pubitemid 34670333)
17. Swarthout JT, D'Alonzo RC, Selvamurugan N, Partridge NC. Parathyroid hormone-dependent signalling pathways regulating genes in bone cells. Gene 2002; 282: 1-17 (Pubitemid 34117557)
18. Luparello C, BurtisWJ, Raue F et al. Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. Mol Cell Endocrinol 1995; 111: 225-232
19. Luparello C, Ginty AF, Gallagher JA et al. Transforming growth factorbeta 1, beta 2, and beta 3, urokinase and parathyroid hormone-related peptide expression in 8701-BC breast cancer cells and clones. Differentiation 1993; 55: 73-80
20. Li H, Seitz PK, Selvanayagam P et al. Effect of endogenously produced parathyroid hormone-related peptide on growth of a human hepatoma cell line (Hep G2). Endocrinol 1996; 137: 2367-2374 (Pubitemid 26155771)
21. Chen HL, Demiralp B, Schneider A et al. Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem 2002; 277: 19374-19381 (Pubitemid 34967444)
22. Yoshimoto K, Yamasaki R, Sakai H et al. Ectopic production of parathyroid hormone by small cell lung cancer in a patient with hypercalcemia. J Clin Endocrinol Metabol 1989; 68: 976-981 (Pubitemid 19127419)
23. Nielsen PK, Rasmussen AK, Feldt-Rasmussen Um BrandtMet al. Ectopic production of intact parathyroid hormone by a squamous cell lung carcinoma in vivo and in vitro. J Clin Endocrinol Metabol 1996; 81: 3793-3796 (Pubitemid 26339955)
24. Seymour JF, Gagel RF, Hagemeister FB et al. Calcitriol production in hypercalcemic and normocalcemic patients with non-Hodgkin lymphoma. Ann Intern Med 1992; 121: 633-640
25. Mawer EB, Hayes ME, Heys SE et al. Constitutive synthesis of 1,25-dihydroxyvitamin D3 by human small cell lung cancer cell line. J Clin Endocrinol Metabol 1994; 79: 554-560 (Pubitemid 24256552)
26. Bertolini DR, Nedwin GE, Bringman TS et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature 1986; 319: 516-518 (Pubitemid 16212936)
27. Yates AJ, Boyce BF, Favarato G et al. Expression of human transforming growth factor alpha by Chinese hamster ovarian tumors in nude mice causes hypercalcemia and increased osteoclastic bone resorption. J Bone Min Res 1992; 7: 847-853
28. Ibbotson KJ, Twardzik DR, D'Souza SM et al. Stimulation of bone resorption in vitro by synthetic transforming growth factor-alpha. Science 1995; 228: 1007-1009
29. Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma. Ann Intern Med 1974; 80: 205-208
30. Bethune JE, Turpin RA. A study of urinary excretion of parathyroid hormone in man. J Clin Invest 1968; 47: 1583-1589
31. Thomas L, Kwok Y, Edelman MJ. Management of paraneoplastic syndromes in lung cancer. Curr Opin Pulm Med 2007; 13: 362-367
32. List AF, Hainsworth JD, Davis BWet al. The syndrome of inappropriate secretion of antidiuretic hormone (SIDAH) in small-cell lung cancer. J Clin Oncol 1986; 4: 1191-1198 (Pubitemid 16043869)
33. Patel AM, Davila DG, Peters SG. Paraneoplastic syndromes associated with lung cancer. Mayo Clin Proc 1993; 68: 278-287 (Pubitemid 23066787)
34. Maurer LH, O'Donnell JF, Kennedy S et al. Human neurophysins in carcinoma of the lung. Cancer Treat Rep 1994; 79: 971-976
35. Bliss DP Jr., Battey JF, Linnoila RI et al. Expression of atrial natriuretic factor gene in small lung cancer tumors and tumor cell lines. J Natl Cancer Inst 1990; 82: 305-310 (Pubitemid 20097704)
36. Moses AM, Scheinman SJ. Ectopic secretion of neurophyseal peptides in patients with malignancy. Endocrinol Metab Clin North Am 1991; 20: 489-506
37. Hansen O, Sorensen P, Hansen KH. The occurence of hyponatremia in SCLC and the influence on prognosis: a retrospective study of 453 patients treated in a single institution in a 10-year period. Lung Cancer 2010; 68: 111-114
38. Vorherr H. Para-endocrine tumor activity with emphasis on ectopic ADH secretion. Oncology 1974; 29: 382-416
39. Nielsen S, Frokiaer J, Marples D et al. Aquaporins in the kidney: from molecule to medicine. Physiol Rev 2002; 82: 205-244
40. Jaenike JR,Waterhouse C. The renal response to sustained administration of vasopressin and water in man. J Clin Endocrinol Metab 1961; 21: 231-242
41. Hannon MJ, Thompson CJ. The syndrome of inappropriate antidiuretic hormone: prevalence, causes, and consequences. Eur J Endocrinol 2010; 162: S5-S12
42. Schrier RW, Gross P, Gheorghiade M et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112 (Pubitemid 44749318)
43. Mendelsohn G, Baylin SB. Ectopic hormone production: biological and clinical implications. Prog Clin Biol Res 1984; 142: 291-316
44. Hansen M. Paraneoplastic syndromes and tumor markers for small-cell and non-small-cell lung cancer. Curr Opin Oncol 1990; 2: 345-351 (Pubitemid 20251601)
45. Mennecier B, Moreau L, Goichot B, Quoix E. Paraneoplastic Cushing's syndrome and small cell bronchial carcinoma. Rev Pneumol Clin 1999; 55: 77-80
46. Shepherd FA, Laskey J, Evans WK et al. Cushing's syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol 1992; 10: 21-27
47. Terzolo M, Reimondo G, Ali A et al. Ectopic ACTH syndrome: molecular bases and clinical heterogeneity. Ann Oncol 2001; 12 (Suppl): S83-S87 (Pubitemid 33069693)
48. Odell WD, Wolfesen AR, Bachelot I, Hirose FM. Ectopic production of lipotropin by cancer. Am J Med 1979; 66: 631-638 (Pubitemid 9146577)
49. Oliver RL, Davis JR, White A. Characterization of ACTH related peptides in ectopic Cushing's syndrome. Pituitary 2003; 6: 119-126 (Pubitemid 38159559)
50. Stewart MF, Crosby SR, Gibson S et al. Small cell lung cancer cell lines secrete predominantly ACTH precursor peptides not ACTH. Br J Cancer 1989; 60: 20-24 (Pubitemid 19187739)
51. White A, Stewart MF, Farrell WE et al. Proopiomelanocortin gene expression and peptide secretion in human small-cell lung cancer cell lines. J Mol Endocrinol 1989; 3: 65-70 (Pubitemid 19177446)
52. Crosby SR, Stewart MF, Farrell WE et al. Comparison of ACTH and ACTH precursor peptides secreted by human pituitary and lung tumour cells in vitro. J Endorcinol 1990; 125: 147-152 (Pubitemid 20129801)
53. Kosmidis P, Krzakowski M. Anemia profiles in patients with lung cancer: what have we learned from the European Cancer Anemia Survey (ECAS)? Lung Cancer 2005; 50: 401-412
54. Glaspy J, Degos L, Dicato M, Demetri GD. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: A retrospective subanalysis of two large, community-based trials. The Oncologist 2002; 7: 126-135 (Pubitemid 34438541)
55. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-1634 (Pubitemid 29479929)
56. Bohlius J, Schmidlin K, Brillant C et al. Erythropoetin or darbepoetin for patients with cancer - meta-analysis based on individual patient data. Cochrane Database Syst Rev 2009; 3: CD007303
57. Glaspy J, Crawford J, Vansteenkiste J et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102: 301-315
58. Goeckenjan G, Sitter H, Thomas M et al. Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 2010; 64 (Suppl. 2): S23-S155
59. Asano S, Urabe A, Okabe T et al. Demonstration of granulopoetic factors in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood 1977; 49: 845-852 (Pubitemid 8093480)
60. Sawyers CL, Golde DW, Quan S, Nimer SD. Production of granulocyte-macrophage colony stimulating factor in two patients with lung cancer, leukocytosis and eosinophilia. Cancer 1992; 69: 1342-1346
61. Matsuguchi T, Okamura S, Kawasaki C et al. Constitutive production of granulocyte colony-stimulating factor and interleukin-6 by a human lung cancer cell line, KSNY: gene amplification and increased mRNA stability. Eur J Haematol 1991; 47: 128-133
62. Tesselaar ME, Osanto S. Risk of venous thromboembolism in lung cancer. Curr Opin Pulm Med 2007; 13: 362-367 (Pubitemid 47472294)
63. Chew HK, Davies AM, Wun T et al. The incidence of venous thromboembolism among patients with lung cancer. J Thromb Haemost 2008; 6: 601-608 (Pubitemid 351404927)
64. Girard P, Raynaud C, Meyer G et al. Thrombosis and lung cancer. Rev Pneumol Clin 2008; 64: 85-91
65. Molnar S, Guglielmone H, Lavarda M et al. Procoagulant factors in patients with cancer. Hematology 2007; 12: 555-559 (Pubitemid 350048067)
66. Goldin-Lang P, Tran QV, Fichtner I et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicates increased blood thrombogenicity and tumour metastasis. Oncol Rep 2008; 20: 123-138
67. Akl EA, Rohilla S, Barba M et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008; 23: CD006649
68. Akl EA, Kamath G, Kim SY et al. Oral anticoagulation for prolonging survival in patients with cancer. Cochrane Database Syst Rev 2007; 18: CD006466
69. Nalluri SR, Chu D, Keresztes R et al. Risk of venous thromboembolism with angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277-2285
70. Hicks LK, Cheung MC, Ding K et al. Venous thromboembolism and nonsmall cell lung cancer: a pooled analysis of National Cancer Institute of Canada Clinical Group trials. Cancer 2009; 115: 5516-5525
71. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer. Chest 1998; 114: 1535-1537 (Pubitemid 128487470)
72. Stenseth JH, Clagett OT, Woolner LB. Hypertrophic pulmonary osteoarthropathy. Dis Chest 1967; 52: 62-68
73. Prakash U. Hypertrophic pulmonary osteoarthropathy and clubbing. In: Sackner MA, ed.Weekly updates: pulmonary medicine; lesson 30 Princeton, NJ: Biomedia 1978: 2-7
74. Myers KA, Farquhar DER. Does this patient have clubbing? JAMA 2001; 286: 341-347
75. Shneerson JM. Digital clubbing and hypertrophic osteoarthropathy. Br J Dis Chest 1981; 75: 113-131
76. Atkinson S, Fox SB. Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. J Pathol 2004; 203: 721-728 (Pubitemid 38714110)
77. Olan F, Portela M, Navarro C et al. Circulating vascular endothelial growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy. J Rheumatol 2004; 31: 614-616 (Pubitemid 38337628)
78. Silveira LH, Martínez-Lavín M, Pineda C et al. Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 2000; 18: 57-62 (Pubitemid 30102045)
79. Pracht M, LeRoux C, Kerjouan M et al. Clubbing and hypertrophic osteoarthropathy in two patients taking long-term bevacizumab for metastatic colorectal cancer. J Gastrointest Cancer 2010 [epub ahead of print May 28, 2010]
80. Uppal S, Diggle CP, Carr IM et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet 2008; 40: 789-793 (Pubitemid 351748871)
81. Amital H, Applbaum YH, Vasiliev L, Rubinow A. Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate. Clin Rheumatol 2004; 23: 330-332 (Pubitemid 39193789)
82. Hill CL, Zhang Y, Sigugeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100 (Pubitemid 32094911)
83. Fujita J, Tokuda M, Bandoh S et al. Primary lung cancer associated with polymyositis/dermatomyositis, a review of the literature. Rheumatol Int 2001; 20: 81-84 (Pubitemid 33779818)
84. Yang Y, Fujita J, Tokuda M et al. Lung cancer associated with several connective tissue diseases: a review of the literature. Rheumatol Int 2001; 21: 106-113
85. Casciola-Rosen L, Nagaraju K, Plotz P et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201: 591-601 (Pubitemid 40289549)
86. Krathen MS, Fiorentino D, Werth VP. Dermatomyositis. Curr Dis Autoimmun 2008; 10: 313-323
87. Levine SM. Cancer and myositis: new insights into an old association. Curr Opin Rheumatol 2006; 18: 620-624 (Pubitemid 44607417)
88. Iorizzi LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: an updated review. J Am Acad Dermatol 2008; 59: 99-112
89. Mollina-Garrido MJ, Guillen-Ponce C, Martinez S, Guirado-Risueno M. Diagnosis and current treatment of neurological paraneoplastic syndromes. Clin Transl Oncol 2006; 8: 796-801
90. Swash M, Schwartz MS. Paraneoplastic syndromes. In: Johnson RT, eds. Current therapy of neurologic disease. Philadelphia, PA: BC Decker 1990: 236-243
91. Elrington GM, Murray NMF, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer: a prospective survey of 150 patients. J Neurol Neurosurg Psychiatry 1991; 54: 764-767
92. Seute T, Leffers P, ten Velde GPM, Twiynstra A. Neurologic disorders in 432 consecutive patients with small cell lung carcinoma. Cancer 2004; 100: 801-806
93. Martina T, Clay AS. A 50-year-old woman with bilateral vocal cord paralysis and hilar mass. Chest 2005; 128: 1028-1031 (Pubitemid 41140543)
94. Anderson NE, Rosenblum MK, Graus F et al. Autoantibodies in paraneoplastic syndromes associated with small-cell lung cancer. Neurology 1988; 38: 1391-1398
95. Szabo A, Dalmau J, Manley G et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to Elva and sex-lethal. Cell 1991; 67: 325-333 (Pubitemid 121001448)
96. King PH, Dropcho EJ. Expression of Hel-N1 and Hel-N2 in small-cell lung carcinoma. Ann Neurol 1996; 39: 679-681 (Pubitemid 26143608)
97. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med 2003; 349: 543-1554
98. Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995; 45: 1873-1878 (Pubitemid 27122961)
99. Carpentier AF, Rosenfeld MR, Delattre JY et al. DNA vaccination with HuD inhibits growth of neuroblastoma inmice. Clin Cancer Res 1998; 4: 2819-2824 (Pubitemid 28523511)
100. Posner JB, Dalmau J. Paraneoplastic syndromes. Curr Opin Immunol 1997; 9: 723-729 (Pubitemid 27485303)
101. Molinuevo JL, Graus F, Serrano C et al. Utility of anti-Hu antibodies in the diagnosis of paraneoplastic sensory neuropathy. Ann Neurol 1998; 44: 976-980 (Pubitemid 28558263)
102. Dalmau J, Graus F, Rosenblum MK et al. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuropathy. Medicine 1992; 71: 9-72
103. Graus F, Keine-Gribert F, Rene R et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-1148 (Pubitemid 32510382)
104. Spiegelman D, Maurer LH, Ware JH et al. Prognostic factors in smallcell carcinoma of the lung: an analysis of 1521 patients. J Clin Oncol 1989; 7: 344-354 (Pubitemid 19075016)
105. Anderson NE, Budde-Steffen C, Rosenblum MK et al. Opsoclonus, myoclonus, ataxia, and encephalopathy in a adults with cancer: a distinct paraneoplastic syndrome. Medicine (Baltimore) 1988; 67: 100-109
106. Bataller L, Graus F, Saiz A, Vilchez JJ and for the Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124: 437-443
107. Margery J, Ferroir JP, Epaud C et al. Paraneoplastic opsoclonus-myoclonus syndrome associated with small-cell lung cancer. Rev Pneumol Clin 2003; 59: 321-324 (Pubitemid 38089530)
108. Hassan KA, Kalemkerian GP, Trobe JD. Long-term survival in paraneoplastic opsoclonus-myoclonus syndrome associated with small cell lung cancer. J Neuroophthalmol 2008; 28: 27-30 (Pubitemid 351416888)
109. Lennon VA, Kryzer TJ, Greismann GE et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. New Engl J Med 1995; 332: 1467-1474
110. Mareska M, Gutmann L. Lambert-Eaton myasthenic syndrome. Semin Neurol 2004; 24: 149-153 (Pubitemid 38971841)
111. Maddison P, Lang B. Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. J Neuroimmunol 2008; 201: 159-162
112. Henson RA, Ulrich H. Encephalomyelitis with carcinoma. In: Henson RA, Ulrich H, eds. Cancer and the nervous system. Oxford: Blackwell Scientific 1982: 314-345
113. Graus F, Cordon-Cardo C, Posner JB. Neuronal antinuclear antibody in sensory neuronopathy from lung cancer. Neurology 1985; 35: 538-543 (Pubitemid 15085073)
114. Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med 1986; 80: 45-52 (Pubitemid 16134802)
115. Clamno GH, Evans WK, Shepherd FA et al. Myasthenic syndrome and small cell cancer of the lung. Arch Intern Med 1984; 144: 999-1000
116. Dropcho EJ. Autoimmune central nervous system paraneoplastic disorders. Ann Neurol 1995; 37: S102-S113
117. Maddison P, Newsom-Davis J. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2005; 18: CD003279
118. Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin 2010; 26: 1363-1375
119. Keime-Guibert F, Graus F, Fleury A et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry 2000; 68: 479-482 (Pubitemid 30248748)
120. Rosenfeld MR, Dalmau J. Current therapies for paraneoplastic neurologic syndromes. Curr Treat Options Neurol 2003; 5: 69-77
121. Vernino S, O'Neill BP, Marks RS et al. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 2004; 5: 55-62 (Pubitemid 38139640)
122. Higgins SP, Freemark M, Prose NS. Akanthosis nigricans: a practical approach to evaluation and management. Dermatol Online J 2008; 14: 2
123. Horiuchi Y, Katsuoka K, Yoshimura H et al. Acanthosis nigricans and Leser-Trelat sign associated with squamous cell carcinoma and adenocarcinoma of the lung. Int J Dermatol 1986; 25: 459-460 (Pubitemid 16025325)
124. Menzies DG, Choo-Kang J, Bruxton PK, Campbell IW. Acanthosis nigricans associated with alveolar cell carcinoma. Thorax 1988; 43: 414-415
125. Onai T, Mori M, Akuzawa M et al. A case of lung carcinoma associated with acanthosis nigricans and increased titer of anti-nuclear antibody. Nippon Naika Gakkai Zhasshi 1989; 78: 1607-1608
126. Krwaczyk M, Mykala-Ciesla J, Kolodziej-Jaskula A. Acanthosis nigricans as a paraneoplastic syndrome. Pol Arch Med Wewn 2009; 119: 180-183
127. Lenzner U, Ramsauer J, PetzoldtWet al. Acanthosis nigricans maligna. Hautarzt 1998; 49: 41-47
128. Schwindt WD, Bernhardt LC, Johnson SAM. Tylosis and intrathoracic neoplasms. Chest 1970; 57: 590-591
129. Nomori H, Horio H, Iga R et al. Squamous cell carcinoma of the lung associated with palmo-plantar hyperkeratosis. Niho Kyobu Shikkan Gakkai Zasshi 1996; 34: 76-79 (Pubitemid 26084059)
130. Engin H, Akdogan A, Altundaq O et al. Non-small-cell lung cancer with nonfamilial diffuse palmoplantar keratoderma. J Exp Clin Cancer Res 2002; 21: 45-47 (Pubitemid 34309231)
131. Burgdorf WHC, Goltz RW. Figurate erythemas. In: Fitzpatrick TB, Eisen AZ, Wolff K et al., eds. Dermatology in Internal Medicine. New York: McGraw-Hill 1987: 1010-1018
132. Bazex A, Griffiths A. Acrokeratosis Paraneoplastica: a new cutaneous marker of malignancy. Br J Dermatol 1980; 103: 301-306
133. Pecora AL, Landsman L, Imgrund SP et al. Acrokeratosis Paraneoplastica (Bazex' Syndrome): Report of a case and Review of the Literature. Arch Dematol 1983; 119: 820-826 (Pubitemid 13009228)
134. Sharma V, Sharma NL, Ranjan N. Acrokeratitis paraneoplastica (Bazex syndrome): Case report and review of the literature. Dermatol Online J 2006; 12: 11
135. Lelbach A, Muzes G, Feher J. Current perspectives of catabolic mediators of cancer cachexia. Med Sci Monit 2006; 13: 168-173
136. Dworzak F, Ferrari P, Gavazzi C et al. Effects of cachexia due to cancer on whole body and skeletal muscle protein turnover. Cancer 1998;82: 42-48 (Pubitemid 28070478)
137. Giordano A, Calvani M, Petillo O et al. Skeletal muscle metabolism in physiology and in cancer disease. J Cell Biochem 2003; 90: 170-186 (Pubitemid 37052319)
138. Harvie MN, Campbell IT, Thatcher N, Baildam A. Changes in body composition in men andwomenwith advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. J Hum Nutr Diet 2003; 16: 323-326 (Pubitemid 37304380)
139. Argiles JM, Moore-Carrasco R, Fuster G et al. Cancer cachexia: the molecular mechanism. Int J Biochem Cell Biol 2003; 35: 405-409
140. Argiles JM, Moore-Carrasco R, Busquets S, Lopez-Soriano FJ. Catabolic mediators as targets for cancer cachexia. Drug Discov Today 2008; 8:838-844
141. Lelbach A, Munez G, Feher J. Molecular mechanisms of cancer cachexia. Orv Hetil 2004; 46: 2329-2334
142. Brink M, Anwar D, Delafontaine P. Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol 2002; 85: 111-121
143. Laviano A, Russo M, Freda F et al. Neurochemical mechanisms for cancer anorexia. Nutrition 2002; 18: 100-105 (Pubitemid 34097728)
144. Schaur RJ, Fellier H, Gleispach H et al. Tumor host relations I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases. J Cancer Res Clin Oncol 1979; 93: 281-285 (Pubitemid 9161038)
145. Knapp ML, al-Sheibani S, Riches PG et al. Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann Clin Biochem 1991; 28: 480-486
146. Cariuk P, Lorite MJ, Todorov PT et al. Induction of cachexia in mice by a product isolated from the urine of cachectic cancer patients. Br J Cancer 1997; 76: 606-613 (Pubitemid 27354674)
147. Hiraki K, Ishiko O, Tisdale M. Mechanisms of depletion of liver glycogen in cancer cachexia. Biochem Biosphys Res Commun 1997; 241: 49-52 (Pubitemid 28033537)
148. Cella D, Davis K, Breitbart W, Curt G, Fatigue Coalition. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 2001; 19: 3385-3391 (Pubitemid 32642191)
149. Ahlberg K, Ekman T, Gaston-Johansson F, Mock V. Assessment and management of cancer-related fatigue in adults. Lancet 2003; 362: 640-6509
150. Chaudhuri A, Behan PO. Fatigue in neurological disorders. Lancet 2004; 363: 978-988 (Pubitemid 38388334)
151. Ronnback L, Hansson E. On the potential of glutamate transport in mental fatigue. J Neuroinflammation 2004; 1: 22
152. Ryan JL, Carroll JK, Ryan EP et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 (Suppl. 1): 22-34
153. Castell LM, Yamamoto T, Phoenix J, Newsholme EA. The role of tryptophan in fatigue and different conditions of stress. Adv Exp Med Biol 1999; 467: 697-704
154. Badawy AA, Morgan CJ, Llewelyn MB et al. Heterogeneity of serum tryptophan concentration and availability to the brain in patients with the chronic fatigue syndrome. J Psychopharmacol 2005; 19: 385-391 (Pubitemid 41003134)
155. Andrews PLR, Morrow GR, Hickok JT. Mechanisms and models of fatigue associated with cancer and its treatment: Evidence of pre-clinical and clinical studies. In: Armes J, Krishnasamy M, Higginson I eds. Fatigue in Cancer. Oxford: Oxford University Press 1988: 51-87
156. Cleare AJ. The neuroendocrinology of chronic fatigue syndrome. Endocr Rev 2003; 24: 236-252 (Pubitemid 36515286)
157. Focan C, Focan-Henrard D, Collette J et al. Cancer-associated alteration of circadian rhythms in carcinoembryonic antigen (CEA) and alpha-feto-protein (AFP) in humans. Anticancer Res 1986; 6: 1137-1144
158. Mormont MC, Levi F. Circadian-system alterations during cancer processes: A review. Int J Cancer 1997; 70: 241-247 (Pubitemid 27107423)
159. Vgontzas AN, Chrousos GP. Sleep, the hypothalamic-pituitary-adrenal axis, and cytokines: Multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin North Am 2002; 31: 15-36 (Pubitemid 34578612)
160. Sephton S, Spiegel D. Circadian disruption in cancer: A neuroendocrine-immune pathway from stress to disease? Brain Behav Immun 2003; 17: 321-328
161. Levin RD, Daehler MA, Grutsch JF et al. Circadian function in patients with advanced non-small-cell lung cancer. Br J Cancer 2005; 93: 1202-1208 (Pubitemid 41679404)
162. McCully KK, Natelson BH, Iotti S et al. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve 1996; 19: 554-560
163. Lane RJ, Barrett MC, Taylor DJ et al. Heterogeneity in chronic fatigue syndrome: Evidence from magnetic resonance spectroscopy of muscle. Neuromuscul Disord 1998; 8: 204-209 (Pubitemid 28246118)
164. Forsyth LM, Preuss HG, MacDowell AL et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Ann Allergy Asthma Immunol 1999; 82: 185-191 (Pubitemid 29106608)
165. Konsman JP, Parnet P, Dantzer R. Cytokine-induced sickness behaviour: Mechanisms and implications. Trends Neurosci 2002; 25: 154-159 (Pubitemid 34164341)